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Abstract
Background: Long-term locoregional control in locally advanced squamous cell carcinoma of the head and neck
(SCCHN) remains challenging. While recent years have seen various approaches to improve outcome by
intensification of treatment schedules through introduction of novel induction and combination chemotherapy
regimen and altered fractionation regimen, patient tolerance to higher treatment intensities is limited by
accompanying side-effects. Combined radioimmunotherapy with cetuximab as well as modern radiotherapy
techniques such as intensity-modulated radiotherapy (IMRT) and carbon ion therapy (C12) are able to limit toxicity
while maintaining treatment effects. In order to achieve maximum efficacy with yet acceptable toxicity, this
sequential phase II trial combines induction chemotherapy with docetaxel, cisplatin, and 5-FU (TPF) followed by
radioimmunotherapy with cetuximab as IMRT plus carbon ion boost. We expect this approach to result in
increased cure rates with yet manageable accompanying toxicity.
Methods/design: The TPF-C-HIT trial is a prospective, mono-centric, open-label, non-randomized phase II trial
evaluating efficacy and toxicity of the combined treatment with IMRT/carbon ion boost and weekly cetuximab in
50 patients with histologically proven locally advanced SCCHN following TPF induction chemotherapy. Patients
receive 24 GyE carbon ions (8 fractions) and 50 Gy IMRT (2.0 Gy/fraction) in combination with weekly cetuximab
throughout radiotherapy. Primary endpoint is locoregional control at 12 months, secondary endpoints are disease-
free survival, progression-free survival, overall survival, acute and late radiation effects as well as any adverse events
of the treatment as well as quality of life (QoL) analyses.
Discussion: The primary objective of TPF-C-HIT is to evaluate efficacy and toxicity of cetuximab in combination
with combined IMRT/carbon ion therapy following TPF induction in locally advanced SCCHN.
Trial Registration: Clinical Trial Identifier: NCT01245985 (clinicaltrials.gov)
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Radiochemotherapy
Platinum-containing radiochemotherapy is the current
standard of care in the conservative treatment approach
for locally advancend squamous cell carcinoma of the
head and neck (SCCHN) [1]. The magnitude of survival
benefit if chemotherapy was applied concomitantly with
radiotherapy was 8% at 5 years as compared to radio-
therapy alone in the meta-analysis undertaken by the
MACH-NC Study Group [2,3]. A much smaller but still
significant survival benefit was detected for all radioche-
motherapy algorithms, whether applied in a neoadju-
vant, adjuvant or concomitant setting with 4% at 5 years
[2,3]. This small but significant survival benefit was
caused mainly by an increased local control rate and
only due to a small effect in reducing distant metastases.
No difference in response to radiochemotherapy could
be detected regarding the tumor site (oropharynx, oral
cavity, larynx, and hypopharynx). In a recent update of
these data, initial results could be confirmed also includ-
ing more recent studies [4]. A second meta-analysis also
including more recent trials in advanced SCCHN found
an overall survival benefit of 12 months when adding
chemotherapy to normally fractionated radiotherapy or
even altered fractionation schedules [5]. A small but sig-
nificant survival benefit of 3.4% can be achieved by
altered fractionation schedules [6]. Hyperfractionation in
particular, leads to a similar absolute improvement in
overall survival (8%) as compared to radiochemotherapy
[6] and accelerated-hyperfractionated radiation yielded
the highest locoregional control rates in the RTOG 90-
03 trial [7] though the effect of the treatment regimen
on overall survival was not significant in this trial.
Accelerated radiation therapy alone, especially when
given as a split course radiation schedule or extremely
accelerated treatments with decreased total dose, does
n o ts e e mt oi m p a c to v e r a l ls u r v i v a l .U s i n ga l t e r e df r a c -
tionation resulted additionally in an increased locoregio-
nal control rate while younger patients apparently have
a higher benefit from altered fractionation schedules [6].
If choosing radiochemotherapy, the results of the
MACH-NC meta-analysis indicated chemotherapy
should be platinum-based [2-4]. Therefore radioche-
motherapy with three cycles cisplatin 100 mg/m2 body
surface given concomitantly can be considered as one of
the main standards; however, this approach is associated
with substantial toxicity and poor compliance.
Improvement of local control and overall survival by
intensified treatment regimen comes at a price:
increased toxicity of the combined approach, high num-
ber of patients unable to complete the full treatment
course (between 5% [8], 15-27% [9] 37% % [10]) or
treatment breaks of > 3days: 17% [8], and the still disap-
pointing long-term results show the need to optimize
these therapeutic combinations. Recent years have seen
the advent of more sophisticated radiotherapy techni-
ques, such as intensity-modulated radiotherapy (IMRT)
and particle therapy, introduction of new chemothera-
peutic combinations with the introduction of taxanes in
the treatment of SCCHN as well as establishment of
molecular targeted agents in the routine treatment of
head and neck cancer.
IMRT
Radiotherapy of head and neck cancer is commonly
accompanied by marked side-effects. Modern techniques
have shown to significantly reduce long-term sequelae
of the treatment [11-13] and have rapidly been inte-
grated into routine clinical practice. Techniques such as
intensity-modulated radiotherapy (IMRT) and image-
guided radiotherapy (IGRT) facilitate application of
higher doses due to stepp gradients and hence higher
conformality and improved sparing of normal tissues.
Despite relative dose escalation, acute and late toxicity
can be reduced. A recent phase III trial comparing
IMRT versus conventional RT could clearly demonstrate
a significant advantage of IMRT in reducing the rate of
xerostomia [14]. In order to reduce toxicity and there-
fore improve radiotherapy regimens, integration of mod-
ern radiotherapy techniques into potential new trial
designs is of fundamental importance.
Particle Therapy
The physical properties of particle beams allow sharp
dose gradients and hence relative dose escalation with
reduction of dose to normal organs. This has been
shown to improve clinical outcome especially in other-
wise relatively radio-resistant tumours [15-18]. Particle
therapy therefore represents another valuable tool for
clinicans to achieve even higher conformality of radia-
tion dose distributions around the tumour. In addition,
heavy charged particles have shown increased relative
biological effectivness (RBE) with an increase in the lin-
ear energy transfer (LET). High-LET radiation response
in tissue is less influenced by oxygenation and less sensi-
tive to variations in the cell cycle and DNA repair.
Photon radiotherapy combined with heavy charged par-
ticles was established in various specalized centers in
the world. Since 1997, more than 400 patients were
treated with carbon ions in a cooperation between the
University of Heidelberg and the GSI in Darmstadt. For
malignant head and neck tumours, particle therapy at
the University of Heidelberg was primarily applied for
patients with adenoid cystic carcinomas in a mixed
beam regimen consisting of IMRT and carbon ion boost
[15,16]. In squamous cell head and neck tumours,
improved outcome in recent trials has been achieved by
improved local control: doses of approximately 70 Gy
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necrotic tumours in a definitive setting. Relative dose
escalation, increased biological effectiveness and oxygen
independence of radiation effect therefore provide a
rationale for the evaluation of particle therapy in the
multi-modality treatment of advanced SCCHN.
EGF-Receptor Inhibition and Radiotherapy
A quantum leap of radiation oncology in SCCHN has
been the establishment of combined radioimmunother-
apy with the monocloncal EGFR-antibody cetuximab for
locally advanced tumors of the head and neck [19,20].
The EGF-receptor is over expressed at high levels in
nearly all squamous cell carcinomas of the head and
neck region. An increased expression of the EGF-recep-
tor is associated with a poor prognosis [21].
The “Bonner” phase III trial compared radiotherapy
with cetuximab with radiotherapy alone for definitive
treatment. In this study, cetuximab was shown to signif-
icantly improve both overall survival and local control.
Apart from skin reactions and a slight increase of infu-
sion reactions no further severe side effects were
reported. In contrast to combined radiochemotherapy
regimen, combination of radiotherapy with cetuximab
did not increase radiotherapy-associated side-effects
such as mucositis [19]. This was also the first study to
demonstrate in a clinical phase III setting that the com-
bination of radiotherapy and a monoclonal antibody
against the EGF-receptor resulted in a clear benefit for
this combination. Retrospective comparison of the data
with prior radiochemotherapy studies showed compar-
able clinical results without the sometimes marked side
effects of the chemotherapy approach [22].
In vitro studies demonstrated that treatment with
Cetuximab inhibited ligand-induced EGFR autopho-
sphorylation and EGFR-dependent cellular response,
including extracellular acidification, cell proliferation,
and production of angiogen i cf a c t o r sb yt u m o u rc e l l s
[23]. Cetuximab alone (monotherapy) eradicated estab-
lished xenograft A431 epidermoid carcinoma tumours
and inhibited tumour growth of breast, renal, pancreatic,
head and neck, prostate, ovarian, and non-small cell
lung carcinomas (NSCLC; including NSCLC xenograft
tumors that express clinically relevant kinase domain
mutants) that expressed 9000 to greater than1.6 × 10
6
EGFR molecules/cell [24]. Cetuximab is being studied as
a monotherapy and in combination with radiotherapy
and/or chemotherapy in several clinical studies. Efficacy
has been observed in various tumour types if given as
monotherapy or in combination with chemotherapy.
Combination therapy of Cetuximab and chemo-thera-
peutic agents resulted in greater inhibition of tumour
growth in colon, lung, breast, ovarian, pancreas, and
head and neck xenograft tumors than either agent alone
[25]. The results of a direct comparison between radio-
therapy and antibody versus radiochemotherapy evalu-
ated in the current RTOG 0522 protocol, initial results
are currently pending but expected for 2011.
Induction chemotherapy for SCCHN
A recently established conservative treatment concept in
SCCHN is the use of induction chemotherapy followed
by radiotherapy or radiochemotherapy. Two fully pub-
lished phase III trials investigated the antitumor activity
and toxicity of two induction chemotherapy regimens of
docetaxel, cisplatin and fluorouracil (TPF) versus stan-
dard cisplatin and 5-FU (PF) [26-28]. Both of these trials
showed a significantly improved overall survival in the
experimental (TPF) arm. In the trial published by Ver-
morken et al. [27] induction chemotherapy was followed
by radiotherapy only. The second trial presented by Pos-
ner et al. [26] induction chemotherapy was followed by
chemoradiotherapy. However, one of the limitations of
this trial were comparatively conservative radiation
doses employed. So far, no phase III trial has yet pub-
lished results of a direct comparison between sequential
TPF induction followed by radiotherapy/chemoradiation
and radiochemotherapy without induction. Preliminary
data presented at ASCO 2009 [29] for the first time
showed a benefit in overall survival in favour of the
sequential regimen. Toxicity was only slightly increased
by the addition of taxanes in all the presented trials.
Nevertheless, a full course - usually consisting of three
cycles - induction chemotherapy with TPF - followed by
af u l lc o u r s eo fr a d i o c h e m o t h e r a p yi sav e r yi n t e n s i v e
treatment concept, few of the patients are able to toler-
ate. Only a limited number of patients can be treated
according to protocol. Several phase III trials arer cur-
rently addressing this issue and are designed to investi-
gated if efficacy can be maintained if radiotherapy in the
sequential approach is combined with cetuximab in
order to reduce toxicity. As explained above, combined
raidioimmunotherapy with cetuximab is able to achieve
comparable control rates as compared to combined
radiochemotherapy in the primary treatment setting
[19,20].
The TPF-C-HIT trial is a phase II trial evaluating
radioimmunotherapy with cetuximab and radiation as
intensity-modulated radiotherapy with carbon ion boost
following TPF induction.
Methods/design
Study design
The TPF-C-HIT trial is a prospective, non-randomized
phase II feasibility trial evaluating locoregional control
(LRC) of radioimmunotherapy with cetuximab as carbon
ion boost and IMRT following standard induction che-
motherapy with TPF as primary endpoint. Secondary
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free survival (PFS), overall survival (OS), acute/late
effects as well as any adverse events of radioimmu-
notherapy as carbon ion boost and IMRT.
Study Characteristics
As explained above, long-term local control in advanced
squamous cell head and neck cancer (SCCHN) remains
a therapeutic challenge. In order to further improve
local control for these patients after standard induction
chemotherapy with TPF, raster-scanned carbon ion
therapy, and radioimmunotherapy as IMRT as the so far
most effective treatment components are combined in
order to achieve the best possible results. This combina-
tion regimen will be tested as to efficacy and toxicity
profile. TPF-C-HIT is a monocentric, open-label, non-
randomised phase II trial.
Patients on the trial receive 2 cycles of induction che-
motherapy with docetaxel, cisplatin, and 5-FU followed
by re-staging imaging. In case of treatment response,
these patients receive their radiation therapy planning
scan and one further cycle of TPF. In case of tumour
progression after 2 cycles of TPF, according to interna-
tional recommendation and guidelines, surgery should
be re-evaluated as salvage treatment. After completion
of the third course of TPF, patients go on to combined
radioimmunotherapy: 8 fractions of carbon ion therapy
at 3 GyE per fraction (total dose 24 GyE) to the primary
tumour and involved lymph nodes are followed by
IMRT to the whole neck at daily fractions of 2 Gy up to
a total dose of 50 Gy. Cetuximab loading dose is given 7
days prior to commencement of radiotherapy followed
by weekly doses throughout the treatment. Treatment
duration will therefore be 108 days (corresponding to
approximately 16 weeks). An overview of the trial sche-
dule is provided in figure 1 (Figure 1). The trial will also
be supervised by an independent data monitoring com-
mittee consisting of two radiation oncologists in accor-
dance with the EMEA guidelines on data monitoring
committees.
Study objectives
To evaluate efficacy and toxicity of radioimmunotherapy
with cetuximab as carbon ion boost and IMRT following
standard induction chemotherapy with TPF. Primary
endpoint is local control at 12 months post completion
of treatment. Secondary endpoints are disease-free survi-
val, progression-free survival, overall survival, acute and
l a t er a d i a t i o ne f f e c t sa sw e l la sa n ya d v e r s ee v e n t s
according to CTCAE v. 4.0, and proteomic and genomic
analyses. For development of prognostic markers, pro-
teomic and genomic analyses are also included in the
secondary endpoints.
Sample size/number of subjects
The main analysis is based on the hypothesis that an
absolute increase of local-regional control rate at 1 year
of 17% is considered to qualify the study treatment as
very promising for additional testing. The decision rules
declared by this design with the above characteristics
are as follows:
H0:p≤ p0 = 63% vs. H1:p≥ p1 = 80%.
p0 = 63% is the clinically “uninteresting” local-regional
control rate at 1 year, corresponding to the null hypoth-
esis H0(according to [19]).
p1 = 80% is the clinically “interesting” local-regional
control rate at 1 year, corresponding to the alternative
hypothesis H1.
Sample size calculation for the TPF-C-HIT trial is
based on a Fleming’s single stage design for phase II
studies. With a significance level of 0.05, a power of
80%, π0 = 0.63 and π1 = 0.8, a sample size of 45 patients
was calculated. Assuming a drop out rate of 10%, 50
need to be recruited for the trial.
Efficacy parameters
Locoregional control (LRC) will be assessed according to
the RECIST criteria [30] with the loss of locoregional
control defined as the first evidence of local progression
or to death due to any cause. Local progression is
defined as a progressive disease (PD) according to
RECIST. The smallest measurement recorded since
treatment start (nadir) will serve as a reference for
further assessments of locoregional control.
Disease-free survival, progression-free survival, and
overall survival are calculated from treatment start (cor-
responding to day 1 of induction chemotherapy) to first
event (i.e. evidence of loco-regional failure, distant fail-
ure, second primary tumor, or death due to any cause.
Figure 1 trial flow-chart.
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events, survival is censored at the time of last documen-
ted evaluation of efficacy/contact. Survival parameters
will be calculated using the Kaplan-Meier estimation
method [31]. All patients who have received cetuximab
at least once will be included in the analysis on an
intent-to-treat basis.
Safety parameters
Adverse events are defined as any untoward medical
occurrence in a patient from the beginning of radioim-
munotherapy (day 57) up to the follow-up visit 12
months post completion of combined radioimmunother-
apy. All adverse events under standard induction che-
motherapy and prior to the first administration of
cetuximab will be recorded as medical history. Adverse
Events will be reported using NCI CTCAE v4.0.
Patient selection
Inclusion criteria
￿ Histologically confirmed locally advanced (stage III or
IV), non-metastatic squamous cell carcinoma of oro-,
hypopharynx and larynx (T2-4, any N, M0),
￿ Oral cavity or oro-, hypopharynx or laynx as the pri-
mary tumor site,
￿ At least one uni-measurable lesion according to the
RECIST,
￿ Karnofsky performance Status > 70%,
￿ Adequate bone marrow function: neutrophils > 1.5 ×
10
9/l, platelets > 100 × 10
9/l, hemoglobin > 10.0 g/dl,
￿ Adequate liver function: Bilirubin < 1.5 mg/dL,
SGOT, SGPT < 3 × ULN, GGT < 5 × ULN,
￿ Adequate renal function: GFR> 70 ml/min.,
￿ Age between 18 to 70 years,
￿ Life expectancy of at least 6 months,
￿ Ability of subject to understand character and indivi-
dual consequences of clinical trial,
￿ Signed written informed consent,
￿ Negative serum/urine Beta-HCG test in women of
childbearing potential,
￿ effective contraception for patients in procreative age
Exclusion criteria
￿ Previous systemic chemotherapy, radiotherapy or sur-
gery for carcinoma of the head and neck or and larynx,
￿ Nasopharyngeal carcinoma,
￿ M1 (distant metastases)
￿ Prior exposure to EGFR pathway targeting therapy,
￿ Participation in other interventional trials within the
last 30 days,
￿ Any surgery within the last 30 days,
￿ Known allergic or hypersensitivity reaction to any
drugs scheduled for the study treatment,
￿ signs of active infection
￿ Symptomatic peripheral neuropathy CTC grade 2 or
higher,
￿ ototoxicity CTC grade 2 or higher, except if due to
trauma caused by tumour mass,
￿ other serious illnesses or medical conditions: ther-
apy-refractory unstable heart disease, congestive heart
failure NYHA °III and °IV; coagulopathies
￿ Other previous malignancy within the past 5 years
except prior, adequately treated basal cell carcinoma of
the skin or pre-invasive carcinoma of the cervix
￿ Significant neurological or psychiatric condition
including dementia or seizures or other serious medical
condition prohibiting the patient’s participation in the
trial by judgement of the investigators
￿ Legal incapacity or limited legal capacity
￿ Positive serum/urine b-HCG/pregnancy
￿ Drug abuse
Study treatment
Induction chemotherapy
Patients receive three cycles of docetaxel/cisplatin/5-FU
(TPF) according to the schedule described by Vermor-
ken et al [27] at the following doses:
Docetaxel 75 mg/m² body surface (d1, d22, d43)
Cisplatin 75 mg/m² body surface (d1, d22, d43)
5-FU 750 mg/m² body surface (d1-5, d22-26, d47-
51)
As a standard, patients of course receive adequate pre-
medication with corticosteroids (dexamethsone) prior to
application of docetaxel, antiemesis, and hydration
according to standard recommendations of the ven-
dours. In addition, patients receive prophylactic antibio-
tic treatment with ciprofloxacine 500 mg po bid for 10
days starting one week after commencement of each
cycle. Dose reductions will be performed as recom-
mended by the vendour.
Pegylated G-CSF is administered prophylactically if a
prior episode of febrile neutropenia or infection with
either delayed recovery of absolute neutrophil count at
day 21 or grade 4 neutropenia (ANC < 0.5 × 10
9/l) per-
sisting for ≥ 7 days was observed during cycle one or
two of TPF.
Immunotherapy
Cetuximab is administered as 400 mg/m² body surface
loading dose 7 days prior to RT-treatment start (d57)
after administration of anti-histamines (dimetindene)
and corticosteroids (dexamethasone).
Weekly administrations of Cetuximab 250 mg/m2
body surface follow for the duration of radiotherapy
from d64.
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Immobilisation/planning examinations
Patients are immobilized using individual thermoplastic
head masks with thermoplastic shoulder fixation. Plan-
ning examinations consist of a planning CT scan (3 mm
slice thickness) with the patient positioned in the indivi-
dual fixation device and contrast-enhanced MRI for 3D
image correlation.
Target volumes
G r o s sT u m o rV o l u m e( G T V )i n c l u d e st h eg r o s sp r i m a r y
tumour or involved node(s) based on clinical and endo-
scopic examinations, CT scan, or other imaging techni-
ques if applicable. Involved lymph nodes are defined as
any lymph nodes > 1 cm or nodes with a necrotic center.
The Clinical Target Volume (CTV) is defined as GTV
plus surrounding areas at risk for containing micro-
scopic disease as delineated by the attending radiation
oncologist. CTV1 includes the GTV with a margin of
approximately 0.2 cm. CTV2 represents the nodal levels
to receive elective irradiation. The CTV margins may be
smaller if the GTV is adjacent to the spinal cord or
other critical normal tissues. Lymph node levels are deli-
neated in accordance with current guidelines and
recommendations [32-36] as follows:
￿ Submental nodes (surgical level IA): In cases where
the floor of mouth or level IB are involved.
￿ Submandibular nodes (surgical level IB): All cases
except primary palate tumours which do not extend
to the tonsil or base of tongue. Only the ipsilateral
level IB is included unless the primary tumour
reaches or crosses the midline. The ipsilateral level
IB must be included in all cases if upper jugular
metastases are found.
￿ Upper deep jugular (junctional, parapharyngeal)
nodes: all cases (at the neck side ipsilateral to the
primary tumour).
￿ Subdigastric (jugulodigastric) nodes, midjugular,
lower neck, and supraclavicular nodes (levels II
through IV): all cases, bilaterally, except for tonsillar
fossa tumours > 1 cm from from the midline and
surgical node negative contralateral neck.
￿ Posterior cervical nodes (level V): all cases, at the
neck side where there is evidence of jugular nodal
metastases.
￿ Retropharyngeal nodes: all cases.
The Planning Target Volume (PTV1 and PTV2)
includes CTV1 and CTV2 with an additional margin in
order to compensate for set-up variability and internal
organ motion. A minimum margin of 0.2 cm around
the CTV in all directions is required to define each
respective PTV, except for situations in which the CTV
is adjacent to spinal cord or other critical normal tis-
sues. In such situations, the margin can be reduced judi-
ciously if image guidance is used regularly.
Planning and RT treatment technique
Carbon ion therapy
Carbon ion therapy treatment planning is carried out
using a dedicated treatment planning system (TPS)
developed for and in co-operation with HIT (Heidelberg
ion beam therapy centre). TPS offers the following func-
tionalities also expected in conventional radiation ther-
apy as well as methods for biological RT treatment
optimization. As ion beams exhibit an increased biologi-
cal effective dose depending on various factors, these
need to be included within the planning algorithm. In
addition, steering parameters for scanned ion beams
need also be calculated by the TPS.
Carbon ion treatment is given at the HIT after inverse
treatment planning in active beam application (raster-
scanning method). A monoenergetic ion beam with a
full-width/half-maximum (FWHM) of 5 mm is extracted
from the accelerator system (synchrotron) and magneti-
cally deflected to subsequently scan all planned iso-ener-
getic slices roughly corresponding to the tumour’s
radiological depth. Using this method almost any
desired dose distribution can be created.
In view of the tolerance dose to organs at risk a dose
of 24 GyE in 8 fractions for carbon ions will be pre-
scribed to the median of the calculated dose distribution
for the target volume (PTV1). Dose specification is
based on biologic equivalent dose because of the high
relative biologic effectiveness (RBE) of carbon ions
Treatment planning aims at covering the PTV1 with the
95%- and 90%-treatment isodose.
Our policy is to avoid under-dosage within a target
volume if the dose constrains for the normal tissue are
not exceeded.
Intensity-modulated radiotherapy (IMRT)
Radiotherapy will be given to the patients only as inten-
sity modulated radiotherapy (IMRT) and must be used
for the entire course of treatment. Intensity-modulated
RT is planned using two commercially available plan-
ning systems: KonRad (Siemens OS) for step-and-shoot
applications or Tomotherapy
®. IMRT hence is delivered
either at a 6 MV-linear accelerator (step-and-shoot tech-
nique) or at a 6 MV tomotherapy unit to a total dose of
50 Gy in 2 Gy/fraction. IMRT image guidance consists
of MV cone-beam CTs which are taken into account for
the calculation of the total applied dose.
Dose Prescription and plan evaluation
IMRT will be given in 25 fractions over approximately
5 weeks. The primary tumour, involved nodes (PTV1)
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per day. The total doses for the PTV1 and the PTV2
will thus be 50.0 Gy± 5%, respectively. Treatment breaks
should be minimized, any break of more than 5 days
will be considered a major protocol violation.
All plans must be normalized such that 95% of the
volume of the PTV1 is covered with the prescribed dose.
In addition the following requirements must be met:
￿ No more than 20% of the PTV1 should receive ≥
110% of the prescribed dose.
￿ No more than 5% of PTV1 or PTV2 should receive
≤ 90% of the prescribed dose.
￿ No more than 2% or 2 cc of tissue outside the
PTVs should receive ≥ 110% of the prescribed dose
to the PTV1.
Critical normal structures constraints
The constraints are applicable for the summation (car-
bon ion and photon IMRT) plan.
￿ Spinal cord: a margin of 0.5-1 cm around the spinal
cord may be added to create a Planning Organ at Risk
Volume (PRV). The dose to any point within the spinal
cord should not exceed 45 Gy to any volume larger
than 0.03 cc.
￿ Parotid glands: the objective is to limit the mean
dose to at least one gland to ≤ 26 Gy; alternatively at
least 20 cc of the combined volume of both parotid
glands to < 20 Gy or at least 50% of one gland to <30
Gy.
￿ Glottic larynx: the dose to the larynx should be kept
<45 Gy whenever feasible.
￿ Brachial plexus: the dose to the brachial plexus must
be limited to ≤ 60 Gy in patients with suspicious level
IV node(s).
￿ M a n d i b l e :7 0G ys h o u l dn o tb ee x c e e d e da ta n y
point.
￿ Brain stem: the tolerated dose is 54 Gy, in volumes
of appox. 1 cc the dose can be 60 Gy.
￿ Unspecified tissue outside the target volumes: ≤
100% of the dose prescribed to PTV2. No more than 5%
of the non-target tissue can receive greater than the
dose to PTV2.
Image guidance (IGRT)
Portal image of each field or orthogonal images that
localize the isocenter placement of IMRT must be
obtained on the first day of therapy. At least weekly set-
up controls using MV cone-beam CTs (cb-CTs) are
required for the IMRT treatment, daily IGRT is required
for carbon ion therapy. Doses applied to the patient by
the acquisition of position controls may be taken into
account for calculation of overall applied dose.
Planning objectives
Parotid glands:
1. Mean dose to either parotid < 26 Gy or
2. At least 50% of the either parotid gland will
receive < 30 Gy or
3. At least 20 ml of the combined volume of both
parotid glands will receive < 20 Gy.
Submandibular/sublingual glands and oral cavity:
Reduce the dose as much as possible.
Planning priorities
Critical normal structure constraints followed by the
prescription goals are the most important planning prio-
rities. The priorities in addressing the protocol aims and
constraints will be in the following order:
1) Critical Normal Structure Constraints,
2) Prescription Goals,
3) Planning Goals: salivary glands.
Treatment schedule/follow-up
Treatment schedule
After inclusion into the trial and the patient’s written
informed conset, the patient receives two cycles of TPF
followed by imaging for re-staging. Without evidence of
progressive disease (PD) according to RECIST, the
patient then receives an individual fixation device con-
sisting of thermoplastic head mask and shoulder fixation
as well as RT treatment planning scans (CT/MRI). Sub-
sequently, patients are administered the third cycle of
TPF (Figure 1). Cetuximab loading dose is applied on
day 57 (7 days prior to RT start). On day 64 (RT wk 1),
the patient receives the first weekly Cetuximab (250 mg/
m² body surface) as well as the first fraction of carbon
ion therapy (Figure 1). First, 8 fractions of C12 heavy
ion boost to the PTV1 to a total dose of 24 GyE at 3
GyE per fraction (5 fractions per week) are applied. Sub-
sequently, the patient receives intensitiy-modulated
photon radiation therapy (IMRT) to the PTV2 to a dose
of 50 Gy at 2 Gy per fraction (5 fractions per week).
Overall, the total dose adds up to 74 GyE in 33
fractions.
Cetuximab is given weekly throughout the course of
radiotherapy (Figure 2).
In case of progressive disease (PD) on the re-staging
examination after two cycles of TPF, surgical salvage
should be re-evaluated.
Follow-up
First follow-up examination including diagnostic, con-
trast-enhanced MRI will be carried out 6 weeks post
completion of radiation treatment. Further controls
including MRI are 3, 6, and 12 months thereafter, in 6
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intervals (Figure 2). Abdominal ultrasound will be car-
ried out q6months, chest-CT q12months. At each fol-
low-up appointment, patients receive a symptom-
oriented clinical examination, also patients’ performance
state (Karnofsky-Index), therapy-associated side effects
as well as potential intercurrent therapy is recorded.
Patients also undergo regular check-ups incl. full ENT
clinical examinations at least every 12 weeks for the first
year of follow-up. Quality of life will be assessed using
the EORTC head and neck questionnaire in 6-monthly
intervals up to 5 years.
Trial duration
The trial for the individual patient is completed after an
18-months follow-up period. In order to include 50
patients, an accrual period of 2 years is expected.
Assessment of efficacy
Assessment of efficacy will be carried out by evaluation
of imaging studies (CT/MRI) at each follow-up. Tumour
response will be evaluated according to the RECIST-cri-
teria [30].
Proteomics and Genomics
If the patient has given (separate) informed consent, 30
mL venous blood will be collected from each subject for
the proteomic examinations prior to the first adminis-
tration of TPF, (e.g. on day -7/day 1), at day 50 (before
the first treatment with cetuximab), day 64, day 73 and
106 of the treatment phase and once at the end of ther-
apy visit (day 108). Thus, the overall volume of blood
samples used for Proteomic/Genomic investigations will
be approximately 120 ml. Following parameters/path-
ways will be investigated:
￿ In order to predict the efficacy of the trimodal
therapy blood will be collceted during therapy and
follow-up to detect and correlate the levels of well
known tumor- and angiogenesis markers (VEGF,
T G F - A l p h a ,b F G F ,I L 8 ,k - r a s ,e t c . )u s i n gE n z y m e -
Linked Immunosorbent Assay (ELISA). Further, pla-
telet protein content (i.e. tumor angiogenesis growth
factors and cytokines) will be analyzed using citrate
b l o o ds a m p l e sa n dc o r r e l a t e dw i t hs e r u m -a n d
plasma- protein results.
￿ In order to perform the genomic analysis, patients’
blood samples are collected as indicated and RNA,
miRNA and DNA isolation will be performed. Based
on an established platform, linear RNA-amplifica-
tion, labelling and hybridization on human genome
wide oligo-arrays (transcriptome analysis) are
planned. DNA samples are used to identify potential
chromosomal aberrations or epigenetic alterations
that might predict treatment response. RNA and
miRNA samples are further analyzed by real time
quantitative RT-PCR to confirm microarray data and
to test a subset of clinical predictors.
The determinations of proteomic and genomic para-
meters will be carried out at the Department of Radia-
tion Oncology in Heidelberg.
No further genetic investigations on the blood col-
lected during the study will be carried out!
Trial organization/coordination
The TPF-C-HIT trial has been designed by the Depart-
ment of Radiation Oncology, and is carried out at the
National Centre for Tumour disease (NCT) Heidelberg,
the Heidelberg Ion Therapy Centre (HIT), and the
department of Radiation Oncology, University of Heidel-
berg. It is an investigator-initiated trial; the Department
of Radiation Oncology is responsible for co-ordination,
overall trial management, registration (clinicaltrials.gov
Identifier: NCT 01245985); EudraCT registration
(EudraCT number: 2009 - 016489- 10), database man-
agement, quality assurance, monitoring, and reporting is
carried out by Alcedis GmbH, Gießen, Germany.
Investigators
Patients are recruited by the Department of Radiation
Oncology, Heidelberg, Germany. Induction chemother-
apy with TPF is given and monitored by the NCT, Hei-
delberg, Germany, combined radioimmunotherapy is
carried out by the Department of Radiation Oncology/
HIT, Heidelberg, Germany.
Figure 2 combined radioimmunotherapy schedule.
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Adverse and serious adverse events are recorded using
NCI common toxicity criteria for adverse events
(CTCAE v. 4). Acute radiation effects are defined as
effects occurring within 90 days from beginning of
radiotherapy. Late effects are defined as effects observed
thereafter. Safety analysis is performed with respect to
frequency of serious adverse events and adverse events
stratified by organ system, severity, causality.
Regular completion of the trial
Patient accrual is completed with inclusion of the last
patient and should extend for approximately 2 years
from trial initiation. Regular trial participation for each
patient terminates 18 months from first administration
of TPF or the patient’s death respectively.
Discontinuation of treatment
￿ Patient wish
￿ Cetuximab treatment delay for more than 2 conse-
cutive weeks,
￿ Occurrence of any grade 4 toxicities related to
cetuximab,
￿ Occurrence of >/= grade 3 allergic/hypersensitivity
reaction related to cetuximab.
￿ Medical condition necessitating treatment termina-
tion and withdrawal of the patient from the trial
￿ Pregnancy
￿ Lack of compliance
Premature termination of the trial
The trial can be prematurely closed or suspended by the
principal investigator (PI) in following cases:
￿ Medical or ethical reasons relevantly affecting the
risk-benefit relationship,
￿ Difficulties in recruitment of subjects suggest unjus-
tifiable prolongation of the study timeline,
￿ Previously unexpected adverse events (in respect of
their nature, severity, duration or outcome) occur with
unjustifiable frequency,
￿ Expected adverse events occur with an unexpectedly
high incidence,
￿ Relevant superiority of patients in one treatment
arm of a comparable clinical trial,
￿ Legal authorities’ decision
The Ethics Committee (EC) and the competent regu-
latory authorities will be informed about premature clo-
sure of the trial. Furthermore, the Ethics Committee(s)
and competent regulatory authorities themselves may
decide to stop or suspend the trial.
If the trial is closed prematurely, the trial material
such as completed, partially completed, and blank CRFs
will be returned to the coordinating investigator.
All involved investigators have to be informed imme-
diately about a cessation or suspension of the trial. The
decision is binding on all investigators.
Ethics, informed consent, and safety
The final protocol was approved by the University of
Heidelberg Medical School ethics committee (AFmo-
167/2010), the German radiation protection authority
(Bundesamt für Strahlenschutz: = BfS) and Paul-Ehrlich
Institute (: = PEI). The trial complies with the Helsinki
Declaration in its recent German version, the Medical
Association’s professional code of conduct, principles of
Good Clinical Practice (GCP) guidelines and the Federal
Data Protection Act. It will be carried out in keeping
with local legal and regulatory requirements. Medical
confidentiality and Federal Data Protection Act will be
followed. Written informed consent is obtained from
each patient in oral and written form.
Discussion
With the introduction of novel radiotherapy techniques
such as IMRT and particle therapy (neutron and carbon
ion therapy), higher local control rates in radioresistant
tumours such as adenoid cystic carcinoma could be
achieved over the last decade [15,16]. Taxane-containing
induction chemotherapy was shown to improve both
response rates and overall survival in advanced SCCHN
[26-28]. On the other hand, novel targeted agents such
as the EGFR antibody cetuximab produced control rates
comparable to standard radiochemotherapy regimens in
retrospective comparisons with a considerably more
favourable toxicity profile [19,20,22].
With the available data, there are various options to
intensify treatment for patients with locally advanced
head and neck tumours: modern radiotherapy techni-
ques provide tools for relative dose escalation within the
tumour, particle therapy may further improve local con-
trol by increased biological effectiveness, and induction
chemotherapy improves long-term survival in these
patients. All of these treatment approaches have shown
clinical feasibility and efficacy as single modalities.
Current standard practice in Europe mostly consists of
combined radiochemotherapy in the conservative man-
agement of locally advanced head and neck tumours
(SCCHN). Management of acute treatment side-effects
in clinical routine shows further intensification is rarely
possible albeit feasible in terms of improved outcome.
Assuming toxicity of combined radioimmunotherapy
being less severe than in radiochemotherapy as demon-
strated by Bonner and co-workers [19], this may still be
feasible following TPF induction.
The TPF-C-HIT trial is a phase II trial to evaluate
three modern treatment algorithms for head and neck
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followed by radioimmunotherapy with cetuximab as
intensity-modulated radiotherapy (C12) plus carbon ion
boost. IMRT is applied in conventional doses per frac-
tion and total dose. The primary tumour and involved
lymph nodes will be boosted by application of a carbon
ion boost in active beam application (raster-scanning
method). Due to these highly sophisticated RT techni-
ques no increased risk of side effects associated with
radiotherapy is expected as compared to conventional
techniques and may even reduce potential side effects in
this setting. Due to the advantages of IMRT and carbon
ion therapy in receiving a better dose distribution in the
target volume improved local control rates may be
achieved. To our knowledge, this is the first clinical trial
evaluation this trimodal treatment regimen.
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